While chimeric antigen receptor T-cell (CART) therapy has shown impressive therapeutic efficacy in several hematologic malignancies, primary or secondary treatment failure remains a significant challenge driving investigators to explore opportunities to improve the functionality of CART products. In...
ORGANISM(S): Homo sapiens (Human)